In a proof‐of‐concept study, eight patients with T2DM who had undergone major surgical procedures were studied with a cross‐over design, between the second and the eighth postoperative day.86 Patients received intravenous GLP‐1 (7‐36) amide (1.2 pmol/kg/min) or placebo over 8 hours, each administered in randomised order in the fasting state. The gene discussed is GCG; the disease is type 2 diabetes mellitus.